Alfonso Gómez de Liaño

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.8K citations

Brca1/2 Mutation, Medicine, Cancer Management +10

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andrés Poveda, Anne Floquet, Jonathan A. Ledermann et al. · The Lancet Oncology · 2021 · 391 citations · Full text

Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer

Bernadett Szabados, Nick van Dijk, Yen Zhi Tang et al. · European Urology · 2017 · 132 citations

Metastatic Urothelial Cancer, Urology, Genitourinary Cancer +9

Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer

Alfonso Gómez de Liaño, Nick van Dijk, Guillermo de Velasco et al. · European Urology · 2019 · 61 citations

Urology, Genitourinary Cancer, Medicine +8

The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma

Pedro C. Barata, Alfonso Gómez de Liaño, Prateek Mendiratta et al. · British Journal of Cancer · 2018 · 47 citations · Full text

Clinical Immunology, Immunodeficiencies, Immunology +24